

Rajin Ahuja  
Chairman of the Board  
Biomarck Pharmaceuticals, Ltd.

Re: Biomarck Capital Raise

Dear Biomarck Investor:

Greetings and I hope this letter finds you in good health and spirits.

As you are aware, Biomarck is in the process of raising up to \$6 million to extend the enrollment of patients in our upcoming clinical trials for Lung Cancer and Acute Respiratory Distress Syndrome. Our plan remains to hopefully initiate both of these trials later this year.

Since our presentation on April 22<sup>nd</sup>, 2016 the raise is progressing well. However, we recognize that all current investors should indeed be rewarded for their past faith in the company. Therefore, the Board has decided to offer current investors the full 20% discount for any investment on or prior to June 15 that is at least pro rata or more. For those who have already sent in your checks and executed documents, this 20% discount will also apply to you as well. In addition, please note that the deadline for your involvement in this financing round has been extended and defined in the attached summary. We welcome new investors such as your friends and colleagues to also participate in this investment. Their opportunity and price point is also available on the attached document and I encourage you to have anyone interested support our company.

It is important to remember that the monies from this raise are explicitly directed to benefit our patients and advance their cause. With the exception of hiring one or two part-time project managers, who will assist with the execution of the trials, Biomarck is concentrating all of these funds on additional patients in these two trials.

I truly appreciate the feedback we received from you regarding the discount for current Biomarck shareholders, and also the time requirement to transfer money and complete the required paperwork. Your message was received and accepted. I urge you to likewise hear our message about Dr. Adler's work and to embrace his dream and Biomarck's vision. Your support in this raise is very much appreciated.

Your investment along with management's efforts can potentially help save a patient's life! Thank you.

A handwritten signature in black ink, appearing to read "Rajin Ahuja", is written over a horizontal line.

Rajin Ahuja  
Chairman

**Overview of Proposed Series G Investment  
In  
biomarck Pharmaceuticals, Ltd. (the “Company”)**

- The Company is raising \$4,000,000 - \$6,000,000 in an offering of Series G Convertible Preferred Stock designated as Series G-1 Convertible Preferred Stock (the “*Series G-1 Preferred Stock*”) and Series G-3 Convertible Preferred Stock (the “*Series G-3 Preferred Stock*”).
- The rights, preferences and privileges relating to the Series G-1 Preferred Stock and Series G-3 Preferred Stock are the same, but the price per share is different due to the discount as set forth below.
- **Valuation / Price Per Share:**
  - The price per share for the Series G-3 Preferred Stock is \$4.99, assuming a pre-money valuation for the Company of approximately \$120 million.
  - There is a 20% discount (\$3.99/share for the Series G-1 Preferred Stock) to **existing** investors investing at least their pro rata share on or before June 15, 2016.
  - There is a 20% discount (\$3.99/share for the Series G-1 Preferred Stock) to **all investors and investor groups** investing at least \$250,000 and pooling all shares together in a voting trust that assigns voting rights to a single current biomarck shareholder (in the case of investor groups) on or before July 15, 2016. After July 15, 2016, there will be no ability to pool investments to receive a discount.
  - There is a 20% discount (\$3.99/share for the Series G-1 Preferred Stock) to **all investors** investing at least \$250,000 on or before August 15, 2016.
  - After August 15, 2016, there will be no discounts to the price per share for the Series G-3 Preferred Stock (\$4.99).
- **Minimum Investment:**
  - For **existing** investors, the minimum investment is their respective pro rata amount.
  - For **new** investors, there is a \$50,000 minimum investment, unless otherwise determined by the Board of Directors.
- **Timeline:**
  - **June 15, 2016:** Existing shareholders must sign investment documents and submit funds to receive the 20% discount described above.
  - **July 15, 2016:** Any investor or investor group with a valid voting trust agreement as described above must sign investment documents and submit minimum funds of \$250,000 to receive the 20% discount described above.
  - **August 15, 2016:** Any single investor must sign investment documents and submit minimum funds of \$250,000 to receive the 20% discount.
  - **No discounts will be offered after August 15, 2016.**
- **Summary of the Company’s capitalization (as of April 26, 2016):**

Number of shares of Common stock outstanding:	<b>3,709,881</b>
Number of shares of Preferred stock outstanding:	<b>13,774,071</b>
Fully diluted shares (including issued and unissued options and warrants):	<b>29,956,236</b>

- **Pooling of Investments for Discount**
  - For an investment group to receive a discount, the investors in the group must pool their investments and sign a voting trust agreement that assigns voting rights in their shares to a single current biomarck shareholder.